The US Food and Drug Administration (FDA) has approved an alternative formulation for Neurocrine Biosciences’ Huntington’s disease therapy, Ingrezza (valbenazine). The new formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback